Archive: December 29 2020
Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Patient Resource: Comparing CAR-NK and CAR T-Cell Therapies
How Do Chimeric Antigen Receptor (CAR) Therapies Differ? Dr. Katy Rezvani, Chief, Section of Cellular Therapy, Department of Stem Cell Transplantation & Cellular Therapy, MD Anderson Cancer Center joins Patient Power Co-founder Andrew Schorr to explain the difference between the two new cell therapies and what this innovation means for ALL, CLL, and NHL patients.
How is CT053 different from other BCMA-directed CAR T-cell therapies?
CT053 consists of autologous T cells genetically modified with a CAR incorporating a fully human BCMA-specific single-chain fragment variant, a 4-1BB intracellular domain, and a CD3 intracellular signaling region. The advantage over other CAR T-cell therapies is that it has a shorter manufacturing time, of 8–10 days, which allows a shorter interval between apheresis and infusion. Learn about the results of an ongoing phase I/II trial evaluating the safety and efficacy of CT053 in patients with relapsed/refractory multiple myeloma.
Iodine apamistamab conditioning led to 100% bone marrow transplant rate and engr...
Treatment with iodine (131I) apamistamab (Iomab-B) conditioning led to a 100% bone marrow transplant rate and engraftment in patients with active relapsed/refractory acute myeloid leukemia who are older than 55 years old, according to results of a single ad hoc interim analysis of the phase 3 SIERRA study.